Trial Profile
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Selexipag (Primary) ; Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms TRITON
- Sponsors Actelion Pharmaceuticals
- 05 Oct 2021 Results assessing efficacy and safety of initial triple oral therapy with macitentan, tadalafil, and selexipag compared with initial double oral therapy with macitentan and tadalafil innaive newly-diagnosed,with PAH published in the Journal of the American College of Cardiology
- 30 Aug 2021 According to a Janssen media release, post hoc analysis from TRITON and GRIPHON presented in as an oral presentation at ESC Congress 2021.
- 30 Aug 2021 Results of post hoc analysis from TRITON and GRIPHON studies presented Janssen media release.